Discovery of ZG-2305, an Orally Bioavailable Factor Inhibiting HIF Inhibitor for the Treatment of Obesity and Fatty Liver Disease
Journal of Medicinal Chemistry · 2025
DOI: 10.1021/acs.jmedchem.4c01698 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Yue Wu und 14 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Design and Optimization, and Department of Chemistry, China Pharmaceutical …. Hauptthemen laut MEDLINE: Obesity. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 58 Literaturangaben. Gefördert von: Wellcome Trust, China Pharmaceutical University, Natural Science Foundation of Jiangsu Province.
Abstract (Originalsprache)
Genetic loss of the 2-oxoglutarate oxygenase factor inhibiting hypoxia-inducible factor (FIH) enhances both glycolysis and aerobic metabolism. FIH is thus a potential target for adiposity control and improving hepatic steatosis. We describe development of a series of novel, potent, and selective FIH inhibitors that occupy both the FIH catalytic site and a recently defined tyrosine conformational-flip pocket. ZG-2305, with a Ki of 79.6 nM for FIH, manifests 38-fold selectivity over the hypoxia-inducible factor (HIF) prolyl hydroxylase PHD2. Oral administration of ZG-2305 in the western-diet induced obesity mouse model results in improved lipid accumulation and recovery from abnormal body weight/hepatic steatosis. Amelioration of nonalcoholic steatohepatitis (NASH) related pathological phenotypes in the HF-CDAA-diet induced NASH mouse model was observed. Preliminary preclinical studies indicate ZG-2305 has good pharmacokinetic properties and an acceptable safety profile. The results imply ZG-2305 is a promising candidate for treatment of obesity and fatty liver disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Design and Optimization, and Department of Chemistry, China Pharmaceutical University, Nanjing 211198, China.
- Department of Pharmaceutical Engineering, China Pharmaceutical University, Nanjing 211198, China.
- Chemistry Research Laboratory, Department of Chemistry and the Ineos Oxford Institute for Antimicrobial Research, University of Oxford, 12 Mansfield Road, Oxford OX1 3TA, United Kingdom.
ORCID-Profile: Yue Wu, Zhihong Li, Fulai Yang, Xiang Li, Christopher J Schofield, Xiaojin Zhang
Förderung
- Wellcome Trust
- China Pharmaceutical University
- Natural Science Foundation of Jiangsu Province
- National Natural Science Foundation of China
- Cancer Research UK
Zitieren
APA
Wu, Y., Zhang, Z., Cai, H., Zhang, W., Zhang, L., Li, Z., Yang, L., Chen, Y., Corner, T. P., Song, Z., Yue, J., Yang, F., Li, X., Schofield, C. J., & Zhang, X. (2025). Discovery of ZG-2305, an Orally Bioavailable Factor Inhibiting HIF Inhibitor for the Treatment of Obesity and Fatty Liver Disease. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c01698
Vancouver
Wu Y, Zhang Z, Cai H, Zhang W, Zhang L, Li Z, et al. Discovery of ZG-2305, an Orally Bioavailable Factor Inhibiting HIF Inhibitor for the Treatment of Obesity and Fatty Liver Disease. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.4c01698
BibTeX
@article{Wu2025,
author = {Wu, Yue and Zhang, Zewei and Cai, Haiping and Zhang, Weiqing and Zhang, Linjian and Li, Zhihong and Yang, Le and Chen, Yafen and Corner, Thomas P and Song, Zhe and Yue, Jie and Yang, Fulai and Li, Xiang and Schofield, Christopher J and Zhang, Xiaojin},
title = {Discovery of ZG-2305, an Orally Bioavailable Factor Inhibiting HIF Inhibitor for the Treatment of Obesity and Fatty Liver Disease},
journal = {Journal of Medicinal Chemistry},
year = {2025},
doi = {10.1021/acs.jmedchem.4c01698}
}
EUVIMED